No black box warning on record for Elahere

As of the latest FDA labeling reviewed, Elahere (MIRVETUXIMAB SORAVTANSINE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Elahere medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Pneumonitis: Withhold ELAHERE for persistent or recurrent Grade 2 pneumonitis and consider dose reduction. Permanently discontinue ELAHERE for Grade 3 or 4 pneumonitis. ( 2.4 , 5.2 ) Peripheral Neuropathy: Monitor patients for new or worsening peripheral neuropathy. Withhold dosage, dose reduce, or permanently discontinue ELAHERE based on the severity of peripheral neuro

No black box warning on record for Elahere

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Pneumonitis: Withhold ELAHERE for persistent or recurrent Grade 2 pneumonitis and consider dose reduction. Permanently discontinue ELAHERE for Grade 3 or 4 pneumonitis. ( 2.4 , 5.2 ) Peripheral Neuropathy: Monitor patients for new or worsening peripheral neuropathy. Withhold dosage, dose reduce, or permanently discontinue ELAHERE based on the severity of peripheral neuro

Elahere Black Box Warning

No black box warning on record for Elahere

Other warnings & precautions

Elahere Black Box Warning

No black box warning on record for Elahere

Other warnings & precautions